Providing for approval from the Department of Health and the Office of Attorney General before certain transactions involving health care entities within this Commonwealth.
SB 322, titled the Health System Protection Act, would create a new state review and approval process for certain health care transactions involving Pennsylvania health care entities and covered entities such as for-profit operators, private equity firms, private equity funds, and real estate investment trusts. The bill prohibits covered transactions that are determined to be “against the public interest,” including those that would significantly reduce competition, increase costs, reduce quality, or limit access to care, especially in rural, low-income, or disadvantaged communities. It also specifically treats health care leaseback agreements as potentially problematic transactions.
Before a covered transaction can close, the health care entity would have to file extensive notice materials with the Attorney General and the Department of Health or obtain a written determination that the deal is not against the public interest. The bill imposes a 90-day waiting period, allows the Attorney General to request additional information and extend review, and authorizes public hearings with livestreaming and posted recordings. If the Attorney General concludes the transaction is against the public interest, the Commonwealth could seek to enjoin it in court or negotiate a voluntary agreement imposing conditions and monitoring requirements.
The bill would significantly expand the oversight role of the Attorney General and the Department of Health in health care mergers, acquisitions, control changes, asset sales, and certain capital distributions. It also requires coordination with other agencies, including the Insurance Department, Department of Aging, and Department of Human Services, and provides for reimbursement of review and monitoring costs by the parties to the transaction. The bill preserves existing authority under the Health Care Facilities Act, antitrust laws, and professional licensing laws, rather than replacing those regimes.
Overall, the bill appears aimed at increasing scrutiny of private equity and other investor-driven health care deals, with a focus on protecting access, competition, and community health care capacity. Because there were no committee transcripts or recorded votes provided, there is no documented legislative debate or vote history to gauge formal support or opposition. The text itself suggests a policy preference for stronger state intervention in health care consolidation and ownership changes, while also allowing exceptions when a transaction is necessary to prevent a facility closure or greater loss of services.
Notable points of contention likely include the breadth of the Attorney General’s authority, the extensive disclosure requirements, the 90-day review period and possible extensions, and the bill’s specific focus on private equity and leaseback transactions. Health care providers and investors may view the measure as burdensome or uncertain for deal-making, while supporters would likely emphasize transparency, community input, and preventing harmful consolidation or service reductions.
SB 322 would add a new layer of state pre-approval and review for covered health care transactions, affecting hospitals, health care facilities, practitioner organizations, and investor-backed entities engaged in acquisitions, control changes, asset transfers, and certain capital distributions. It would amend the practical regulatory landscape by giving the Attorney General and Department of Health authority to review, condition, delay, or block transactions deemed against the public interest, while preserving existing oversight under the Health Care Facilities Act, antitrust law, and other agency review processes.
Based on the bill text, the measure is framed as a consumer- and community-protection bill, with an emphasis on preserving competition, access, and quality of care. No committee testimony or vote record was provided, so there is no direct evidence of legislative sentiment from debate or roll calls. The drafting suggests support from sponsors concerned about consolidation and investor ownership in health care, but the scope of the review process indicates the bill would likely draw concern from provider, investor, and transaction stakeholders.
The main points of contention are likely to be the bill’s broad definition of covered entities and transactions, the Attorney General’s discretion to determine what is against the public interest, and the extensive information and public-hearing requirements. Opponents may argue that the bill could slow or deter beneficial transactions, especially rescue deals for struggling facilities, while supporters are likely to argue that stronger oversight is needed to prevent reduced competition, higher costs, and loss of access, particularly in rural and underserved communities. The bill’s explicit inclusion of private equity firms, private equity funds, REITs, and health care leaseback agreements is also likely to be controversial.